[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631594":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":7,"responsibleParty":21,"collaborators":7,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":7,"acronym":7,"eligibilityCriteria":28,"healthyVolunteers":25,"sex":7,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":29,"phases":7,"briefSummary":30,"conditions":31,"keywords":7,"overallStatus":34,"whyStopped":7,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":39,"locationsCount":7},{"fullName":5,"class":6},"Regeneron Pharmaceuticals","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":12},"DRUG","ubamatamab",[13,14],"R4018","MUC16xCD3",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Requests for compassionate use must be initiated by a treating physician Physicians should contact","CONTACT","844-734-6643","Managedaccessrequests@regeneron.com",{"type":22,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100631594","compassionate-use-of-ubamatamab-100631594",false,"NCT07502716","Compassionate Use of Ubamatamab","Eligibility will be determined during the application review process.","EXPANDED_ACCESS","Provide Compassionate Use of Ubamatamab",[32,33],"Renal Medullary Carcinoma (RMC)","Epithelioid Sarcoma","AVAILABLE","2026-03-24",{"date":37,"type":38},"2026-03-31","ACTUAL",{"name":5,"class":6}]